Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-09-024698
Filing Date
2009-05-06
Accepted
2009-05-06 14:28:04
Documents
1
Period of Report
2009-05-06

Document Format Files

Seq Description Document Type Size
1 MAIN DOCUMENT DESCRIPTION c84930_4x0.html 4  
1 MAIN DOCUMENT DESCRIPTION c84930_4x0.xml 4 4742
  Complete submission text file 0001209191-09-024698.txt   7279
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Reporting) CIK: 0001030617 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-50743 | Film No.: 09800877

Mailing Address LICHSTRASSE 35 BASEL SWITZERLAND CH 4056
Business Address LICHSTRASSE 35 BASEL SWITZERLAND V8 CH 4056
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 000-50743 | Film No.: 09800878
SIC: 2834 Pharmaceutical Preparations

Mailing Address 300 THIRD STREET CAMBRIDGE MA 02142
Business Address 300 THIRD STREET CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Issuer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations